Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma

Tanaya Shree, MDPhDBA, Michael S. Khodadoust, MD PhD, Debra K. Czerwinski, BA, Matthew J. Frank, MD PhD, Sara Beygi, MD, Steven R. Long, MD, Brock Martin, MD, Ronald Levy, MD

Blood (2020) 136 (Supplement 1): 48.

https://doi.org/10.1182/blood-2020-141377

Published: 2020

Journal Articles

Single Cell Analysis of Serial Lymphoma Biopsies Reveals Dynamic Immune Modulation and Predictors of Response in Patients Undergoing in Situ Vaccination

Tanaya Shree, MDPhDBA, Sarah Haebe, MD, Anuja Sathe, PhD, Grady Day, Debra K. Czerwinski, BA, HoJoon Lee, PhD, Susan Grimes, BSc, Steven R. Long, MD, Brock Martin, MD, Hanlee Ji, MD, Ronald Levy, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-141672

Published: 2020

Journal Articles

A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma

Tanaya Shree, MD PhD, Michael S. Khodadoust, MD PhD, Debra K. Czerwinski, BA, Matthew J. Frank, MD PhD, Wan X. Hong, MD, Rachel Greenstein, Steven R. Long, MD, Brock Martin, MD, Ronald Levy, MD

Blood (2019) 134 (Supplement_1): 2825.

https://doi.org/10.1182/blood-2019-129661

Published: 2019

Journal Articles

Single Cell RNA Sequencing of Serial Tumor and Blood Biopsies from Lymphoma Patients on an in Situ Vaccination Clinical Trial

Tanaya Shree, MD PhD BA, Anuja Sathe, PhD, Debra K. Czerwinski, BA, Steven R. Long, MD, Hanlee Ji, MD, Ronald Levy, MD

Blood (2018) 132 (Supplement 1): 4107.

https://doi.org/10.1182/blood-2018-99-119925

Published: 2018

Journal Articles

Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies

Nasheed Hossain, MD, Bita Sahaf, PhD, Matthew Abramian, PhD, Jay Y. Spiegel, MD, Katie Kong, Stephen Kim, Sharon Mavroukakis, Jean Oak, MD PhD, Yasodha Natkunam, MD PhD, Everett H Meyer, MD PhD, Matthew J. Frank, MD PhD, Steven A Feldman, PhD, Steven R. Long, MD, Haiying Qin, MS, Terry J. Fry, MD, Lori S Muffly, MD, Crystal L. Mackall, MD, David B. Miklos, MD PhD

Blood (2018) 132 (Supplement 1): 490.

https://doi.org/10.1182/blood-2018-99-110142

Published: 2018

Journal Articles

Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 576.

https://doi.org/10.1182/blood-2018-99-113261

Published: 2018

Journal Articles

Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy

Jean Oak, MD PhD, Jay Y. Spiegel, MD, Bita Sahaf, PhD, Yasodha Natkunam, MD PhD, Steven R. Long, MD, Nasheed Hossain, MD, Crystal L. Mackall, MD, Katherine A. Kong, David B. Miklos, MD PhD

Blood (2018) 132 (Supplement 1): 4656.

https://doi.org/10.1182/blood-2018-99-120206

Published: 2018

Journal Articles

Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and Non-Injected Tumor Sites in Patients with Low-Grade Lymphoma

Debra K. Czerwinski, BA, Matthew J. Frank, MD PhD, Tanaya Shree, MD PhD BA, Michael S Khodadoust, MD PhD, Steven R. Long, MD, Ronald Levy, MD

Blood (2018) 132 (Supplement 1): 1612.

https://doi.org/10.1182/blood-2018-99-119931

Published: 2018

Journal Articles

SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial

Ronald Levy, MD, Patrick M. Reagan, MD, Jonathan W. Friedberg, MD, Nancy L Bartlett, MD, Leo I. Gordon, MD, Abraham Leung, MD, Joanna Peterkin, MD MS, Biao Xing, Robert Coffman, PhD, Robert Janssen, MD, Albert Candia, PhD, Michael Khodadoust, MD PhD, Matthew J. Frank, MD PhD, Steven R Long, MD, Debra K Czerwinski, Michael Chu, MD

Blood (2016) 128 (22): 2974.

https://doi.org/10.1182/blood.V128.22.2974.2974

Published: 2016

Journal Articles

Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cyotmetry in Previously Untreated Patients

Debra K Czerwinski, Steven R Long, MD, Michael Khodadoust, MD PhD, Matthew J. Frank, MD PhD, Adel Kardosh, MD PhD, Ami Okada, PhD, Sophie Robinson, Ronald Levy, MD

Blood (2016) 128 (22): 2947.

https://doi.org/10.1182/blood.V128.22.2947.2947

Published: 2016

Journal Articles

Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN

Debra K Czerwinski, Steven R Long, MD, Michael Khodadoust, MD PhD, Matthew J. Frank, MD PhD, Michael P. Chu, MD, Ami Okada, PhD, Kathleen A McDonald, BA, Holbrook E Kohrt, MD PhD, Nancy L Bartlett, MD, Patrick M. Reagan, MD, Jonathan W. Friedberg, MD MMSc, Leo I. Gordon, MD, Robert Coffman, PhD, Robert Janssen, MD, Ronald Levy, MD

Blood (2015) 126 (23): 1539.

https://doi.org/10.1182/blood.V126.23.1539.1539

Published: 2015

NARROW

Intratumoral CpG, Local Radiation, and Oral Ibrutinib Combine to Produce Effective in Situ Vaccination in Patients with Low-Grade B-Cell Lymphoma

Single Cell Analysis of Serial Lymphoma Biopsies Reveals Dynamic Immune Modulation and Predictors of Response in Patients Undergoing in Situ Vaccination

A Phase I/II Trial of Intratumoral CpG, Local Low-Dose Radiation, and Oral Ibrutinib in Patients with Low-Grade B-Cell Lymphoma

Single Cell RNA Sequencing of Serial Tumor and Blood Biopsies from Lymphoma Patients on an in Situ Vaccination Clinical Trial

Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies

Elevated Axicabtagene Ciloleucel (CAR-19) Expansion By Immunophenotyping Is Associated with Toxicity in Diffuse Large B-Cell Lymphoma

Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy

Intratumoral Injection of CpG-ODN Plus Systemic Ibrutinib Induces an Anti-Tumor Immune Response Affecting T Cell Subsets in the Microenvironment of Both Injected and Non-Injected Tumor Sites in Patients with Low-Grade Lymphoma

SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial

Examining the Heterogeneity of Follicular Lymphoma By Multi-Parameter Flow Cyotmetry in Previously Untreated Patients

Regulatory T Cells Are Depleted in Low-Grade Lymphoma By the Combination of Local Low-Dose Radiation Followed By Intratumoral CpG-ODN

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only